InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,509.43
(
1.34%
)
US TECH 100
18,817.20
(
2.82%
)
Dow Jones
40,924.43
(
0.44%
)
Brent Oil
80.72
(
2.74%
)
Bitcoin
66,494.76
(
0.49%
)
Post# of 252753
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 120168
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 218510

Sunday, 04/15/2018 8:03:32 PM

Sunday, April 15, 2018 8:03:32 PM

Post# of 252753
Re: Keytruda in adjuvant melanoma

Apparently, this is a disease setting where PD-L1 expression doesn’t matter as much as it usually does. In the excerpt you posted, the HR for RFS* was 0.67 for the entire trial and 0.64 (a little better) for the PD-L1-positive subgroup.

*a/k/a DFS; equivalent to PFS in settings where all patients begin the trial with no observed disease.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up